Clinical trials: Small Intestinal Bacterial Overgrowth
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin
The goal of this clinical trial is to test the effectiveness of probiotic bacterial supplements as an additional therapeutic modality in patients with small intestine bacterial overgrowth who receive oral antibiotic treatment…
- Conditions
- Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO
- Trial name
- NCT06223685
- Testing
- Rifaximin (Xifaxan) 1200mg/day, Probiotic, XIFAXAN® (Rifaximin) 1600mg/day
- Where
- Poland
- Volunteers
- 129 people
- Sponsor
- Pomeranian Medical University Szczecin
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing
The objective of this study is to compare the efficacy of prokinetics versus antibiotics versus a combination of antibiotics plus prokinetics in the eradication of Small-Intestinal Bacterial Over-Growth Syndrome (SIBO) in those…
- Trial name
- SIBO (NCT01324895)
- Where
- United States
- Volunteers
- 944 people
- Sponsor
- University of Florida
Irritable Bowel Syndrome
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms.
- Trial name
- NCT02565654
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University